Search

Your search keyword '"Leis, Jose F."' showing total 795 results
Start Over Author "Leis, Jose F."
795 results on '"Leis, Jose F."'

101. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice

Author

Koehler, Amber B., primary, Leung, Nelson, additional, Call, Timothy G., additional, Rabe, Kari G., additional, Achenbach, Sara J., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Wang, Yucai, additional, Muchtar, Eli, additional, Hayman, Suzanne R., additional, Hampel, Paul J., additional, Finnes, Heidi D., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2020
Full Text
View/download PDF

102. Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond theCLLinternational prognostic index

Author

Kleinstern, Geffen, primary, O'Brien, Daniel R., additional, Li, Xing, additional, Tian, Shulan, additional, Kabat, Brian F., additional, Rabe, Kari G., additional, Norman, Aaron D., additional, Yan, Huihuang, additional, Vachon, Celine M., additional, Boddicker, Nicholas J., additional, Call, Timothy G., additional, Parikh, Sameer A., additional, Bruins, Laura, additional, Bonolo de Campos, Cecilia, additional, Leis, Jose F., additional, Shanafelt, Tait D., additional, Ding, Wei, additional, Cerhan, James R., additional, Kay, Neil E., additional, Slager, Susan L., additional, and Braggio, Esteban, additional

Published
2020
Full Text
View/download PDF

103. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation

Author

Mountjoy, Luke, primary, Jain, Tania, additional, Kunze, Katie L., additional, Khera, Nandita, additional, Sproat, Lisa Z., additional, Jennifer, Woodburn, additional, McCallen, Margaret, additional, Leis, Jose F., additional, Noel, Pierre, additional, Slack, James L., additional, and Palmer, Jeanne, additional

Published
2020
Full Text
View/download PDF

104. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

Author

Parikh, Sameer A., primary, Achenbach, Sara J., additional, Call, Timothy G., additional, Rabe, Kari G., additional, Ding, Wei, additional, Leis, Jose F., additional, Kenderian, Saad S., additional, Chanan‐Khan, Asher A., additional, Koehler, Amber B., additional, Schwager, Susan M., additional, Muchtar, Eli, additional, Fonder, Amie L., additional, McCullough, Kristen B., additional, Nedved, Adrienne N., additional, Smith, Matthew D., additional, Slager, Susan L., additional, Kay, Neil E., additional, Finnes, Heidi D., additional, and Shanafelt, Tait D., additional

Published
2020
Full Text
View/download PDF

105. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families

Author

Goldin, Lynn R., Lanasa, Mark C., Slager, Susan L., Cerhan, James R., Vachon, Celine M., Strom, Sara S., Camp, Nicola J., Spector, Logan G., Leis, Jose F., Morrison, Vicki A., Glenn, Martha, Rabe, Kari G., Achenbach, Sara J., Algood, Sallie D., Abbasi, Fatima, Fontaine, Laura, Yau, Michelle, Rassenti, Laura Z., Kay, Neil E., Call, Timothy G., Hanson, Curtis A., Weinberg, Brice J., Marti, Gerald E., and Caporaso, Neil E.

Published
2010
Full Text
View/download PDF

106. Differential transcriptomic profiling in ibrutinib‐naïve versus ibrutinib‐resistant Richter syndrome.

Author

Wang, Hanyin, Tian, Shulan, Zhao, Qing, Blumenschein, Wendy, Yearley, Jennifer H., Secreto, Charla R., Sinha, Sutapa, Call, Timothy G., Wang, Yucai, Parikh, Sameer A., Kenderian, Saad S., He, Rong, Leis, Jose F., Shi, Min, Van Dyke, Daniel L., Kay, Neil E., Slager, Susan L., Braggio, Esteban, Yan, Huihuang, and Ding, Wei

Subjects
RICHTER syndrome, FLUDARABINE, CHRONIC leukemia, TRANSCRIPTOMES, RITUXIMAB, LYMPHOBLASTIC leukemia, BRUTON tyrosine kinase, CHRONIC lymphocytic leukemia
Abstract

Despite the advances of targeted therapeutics in chronic lymphocytic leukemia (CLL), 3%-20% of CLL patients transform into aggressive lymphoma (commonly diffuse large B cell lymphoma, DLBCL) known as Richter's syndrome (RS).1 Patients who develop RS typically do not respond to standard chemotherapy and have poor overall survival (less than 1 year).1 Thus, translational studies to understand RS pathogenesis particularly regards to drug resistance, could provide insights for therapeutic development. Similar to the results from ibrutinib-treated CLL,9 we observed downregulation of I MS4A1 i in ibrutinib-treated RS, which may be associated with a lack of efficacy in adding rituximab to ibrutinib in CLL.10 The serial analysis for RS9 samples showed upregulation of several chemokine genes in the ibrutinib-resistant RS phase, suggesting their possible contribution in RS transformation. In this study we investigated transcriptomic profiles of six ibrutinib-resistant and five ibrutinib-naïve RS-involved lymphoid tissue using samples collected from a cohort of refractory RS patients. Ibrutinib has been shown to inhibit BCR and NF B signaling in CLL cells from both peripheral blood and tissue compartments.6 However, in our study we observed upregulation of several NF I i B-related genes in ibrutinib-resistant RS. [Extracted from the article]

Published
2022
Full Text
View/download PDF

107. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.

Author

Muchtar, Eli, Koehler, Amber B., Johnson, Michael J., Rabe, Kari G., Ding, Wei, Call, Timothy G., Leis, Jose F., Kenderian, Saad S., Hayman, Suzanne R., Wang, Yucai, Hampel, Paul J., Holets, Matthew A., Darby, Heather C., Slager, Susan L., Kay, Neil E., Miao, Congrong, Canniff, Jennifer, Whitaker, Jennifer A., Levin, Myron J., and Schmid, D. Scott

Published
2022
Full Text
View/download PDF

108. 239 - Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Author

Wiedmeier-Nutor, Julia Erin, Iqbal, Madiha, Muñoz, Javier, Bezerra, Evandro D., Garcia Robledo, Juan Esteban, Bansal, Radhika, Johnston, Patrick B, Hathcock, Matthew, Larsen, Jeremy T, Bergsagel, P Leif, Wang, Yucai, Reeder, Craig, Leis, Jose F., Fonseca, Rafael, Palmer, Jeanne, Warsame, Rahma, Kourelis, Taxiarchis, Hayman, Suzanne R, Dingli, David, Kapoor, Prashant, Villasboas, Jose C, Paludo, Jonas, Bennani, Nora N, Ansell, Stephen, Castro, Januario E., Kharfan-Dabaja, Mohamed A., Lin, Yi, Vergidis, Paschalis, Murthy, Hemant, and Rosenthal, Allison

Published
2022
Full Text
View/download PDF

109. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

Author

Hampel, Paul J., primary, Call, Timothy G., additional, Ding, Wei, additional, Muchtar, Eli, additional, Kenderian, Saad S., additional, Wang, Yucai, additional, Leis, Jose F., additional, Witzig, Thomas E., additional, Koehler, Amber B., additional, Fonder, Amie L., additional, Schwager, Susan M., additional, Rabe, Kari G., additional, Van Dyke, Daniel L., additional, Braggio, Esteban, additional, Slager, Susan L., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2019
Full Text
View/download PDF

110. BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Author

Hampel, Paul J., primary, Call, Timothy G., additional, Achenbach, Sara J., additional, Rabe, Kari G, additional, Ding, Wei, additional, Muchtar, Eli, additional, Kenderian, Saad S., additional, Wang, Yucai, additional, Koehler, Amber, additional, Fonder, Amie, additional, Leis, Jose F., additional, Schwager, Susan M., additional, Van Dyke, Daniel L., additional, Braggio, Esteban, additional, Slager, Susan L., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2019
Full Text
View/download PDF

111. The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

Author

Archibald, William J, primary, Call, Timothy G., additional, Achenbach, Sara J., additional, Rabe, Kari G, additional, Hanson, Curtis A., additional, Ding, Wei, additional, Koehler, Amber, additional, Muchtar, Eli, additional, Hayman, Suzanne R., additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Wang, Yucai, additional, Fonder, Amie, additional, Shi, Min, additional, Van Dyke, Daniel L., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2019
Full Text
View/download PDF

112. Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Author

Kleinstern, Geffen, primary, O'Brien, Daniel R, primary, Kabat, Brian, primary, Rabe, Kari G, primary, Norman, Aaron D., primary, Yan, Huihuang, primary, Vachon, Celine M., primary, Tian, Shulan, primary, Call, Timothy G., primary, Parikh, Sameer A., primary, Leis, Jose F., primary, Ding, Wei, primary, Cerhan, James R., primary, Kay, Neil E., primary, Braggio, Esteban, primary, and Slager, Susan L., primary

Published
2019
Full Text
View/download PDF

113. A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Author

Parikh, Sameer A., primary, Muchtar, Eli, additional, Laplant, Betsy, additional, Ding, Wei, additional, Ailawadhi, Sikander, additional, Koehler, Amber, additional, Call, Timothy G., additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Fonder, Amie, additional, Shi, Min, additional, Chanan-Khan, Asher A., additional, Pettinger, Adam, additional, Witzig, Thomas E., additional, Thompson, Carrie A., additional, Villasboas, Jose C, additional, Sholes, Jessica M, additional, Hanson, Curtis A., additional, Braggio, Esteban, additional, Medina, Kay L., additional, Slager, Susan L., additional, and Kay, Neil E., additional

Published
2019
Full Text
View/download PDF

114. Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Author

Shanafelt, Tait D., primary, Wang, Victoria, primary, Kay, Neil E., primary, Hanson, Curtis A., primary, O'Brien, Susan M., primary, Barrientos, Jacqueline C., primary, Jelinek, Diane F, primary, Braggio, Esteban, primary, Leis, Jose F., primary, Zhang, Cong Christina, primary, Coutre, Steven, primary, Barr, Paul M., primary, Cashen, Amanda F, primary, Mato, Anthony R., primary, Singh, Avina, primary, Mullane, Michael P., primary, Little, Richard F., primary, Erba, Harry P., primary, Stone, Richard M., primary, Litzow, Mark, primary, and Tallman, Martin S., primary

Published
2019
Full Text
View/download PDF

115. Abstract 4466: Somatic mutations within chronic lymphocytic leukemia (CLL) putative driver genes are associated with outcomes beyond the CLL international prognostic index (CLL-IPI)

Author

Kleinstern, Geffen, primary, O’Brien, Daniel R., additional, Kabat, Brian F., additional, Chaffee, Kari G., additional, Norman, Aaron D., additional, Call, Timothy G., additional, Parikh, Sameer A., additional, Leis, Jose F., additional, Ding, Wei, additional, Cerhan, James R., additional, Kay, Neil E., additional, Slager, Susan L., additional, and Braggio, Esteban, additional

Published
2019
Full Text
View/download PDF

116. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center

Author

Wang, Yucai, primary, Tschautscher, Marcella A., additional, Rabe, Kari G., additional, Call, Timothy G., additional, Leis, Jose F., additional, Kenderian, Saad S., additional, Kay, Neil E., additional, Muchtar, Eli, additional, Van Dyke, Daniel L., additional, Koehler, Amber B., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Parikh, Sameer A., additional, and Ding, Wei, additional

Published
2019
Full Text
View/download PDF

117. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

Author

Hampel, Paul J., primary, Ding, Wei, additional, Call, Timothy G., additional, Rabe, Kari G., additional, Kenderian, Saad S., additional, Witzig, Thomas E., additional, Muchtar, Eli, additional, Leis, Jose F., additional, Chanan-Khan, Asher A., additional, Koehler, Amber B., additional, Fonder, Amie L., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Shanafelt, Tait D., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2019
Full Text
View/download PDF

120. Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?

Author

Jain, Tania, primary, Kunze, Katie L., additional, Khetarpal, Banveet K., additional, McCallen, Margaret R., additional, Betcher, Jeffrey A., additional, Ofori, Henry T., additional, Khera, Nandita, additional, Slack, James L., additional, Leis, Jose F., additional, Sproat, Lisa Z., additional, Noel, Pierre, additional, and Palmer, Jeanne, additional

Published
2019
Full Text
View/download PDF

121. IGHtranslocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes

Author

Fang, Hong, primary, Reichard, Kaaren K., additional, Rabe, Kari G., additional, Hanson, Curtis A., additional, Call, Timothy G., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Muchtar, Eli, additional, Schwager, Susan M., additional, Leis, Jose F., additional, Chanan-Khan, Asher A., additional, Slager, Susan L., additional, Braggio, Esteban, additional, Smoley, Stephanie A., additional, Kay, Neil E., additional, Shanafelt, Tait D., additional, Van Dyke, Daniel L., additional, and Parikh, Sameer A., additional

Published
2019
Full Text
View/download PDF

122. Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index.

Author

Kleinstern, Geffen, O'Brien, Daniel R., Li, Xing, Tian, Shulan, Kabat, Brian F., Rabe, Kari G., Norman, Aaron D., Yan, Huihuang, Vachon, Celine M., Boddicker, Nicholas J., Call, Timothy G., Parikh, Sameer A., Bruins, Laura, Bonolo de Campos, Cecilia, Leis, Jose F., Shanafelt, Tait D., Ding, Wei, Cerhan, James R., Kay, Neil E., and Slager, Susan L.

Published
2020
Full Text
View/download PDF

123. Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Author

Hampel, Paul J., Call, Timothy G., Ding, Wei, Muchtar, Eli, Kenderian, Saad S., Wang, Yucai, Leis, Jose F., Witzig, Thomas E., Koehler, Amber B., Fonder, Amie L., Schwager, Susan M., Rabe, Kari G., Van Dyke, Daniel L., Braggio, Esteban, Slager, Susan L., Kay, Neil E., and Parikh, Sameer A.

Published
2020
Full Text
View/download PDF

124. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Author

Sinha, Sutapa, primary, Boysen, Justin C., additional, Chaffee, Kari G., additional, Kabat, Brian F., additional, Slager, Susan L., additional, Parikh, Sameer A., additional, Secreto, Charla R., additional, Call, Tim, additional, Shanafelt, Tait D., additional, Leis, Jose F., additional, Warner, Steven L., additional, Bearss, David J., additional, Ghosh, Asish K., additional, and Kay, Neil E., additional

Published
2018
Full Text
View/download PDF

125. Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Author

Boddicker, Nicholas J, primary, O'Brien, Daniel R, additional, Braggio, Esteban, additional, Achenbach, Sara J., additional, Chaffee, Kari G., additional, Norman, Aaron D., additional, Vachon, Celine M., additional, Kabat, Brian, additional, Call, Timothy G., additional, Parikh, Sameer A., additional, Leis, Jose F., additional, Ding, Wei, additional, Muchtar, Eli, additional, Cerhan, James R., additional, Shanafelt, Tait D., additional, Kay, Neil E., additional, Caporaso, Neil E, additional, and Slager, Susan L., additional

Published
2018
Full Text
View/download PDF

128. Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation

Author

Wang, Yucai, primary, Tschautscher, Marcella, additional, Chaffee, Kari G., additional, Call, Timothy G., additional, Leis, Jose F., additional, Kenderian, Saad S., additional, Kay, Neil E., additional, Muchtar, Eli, additional, Van Dyke, Daniel L., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Parikh, Sameer A., additional, and Ding, Wei, additional

Published
2018
Full Text
View/download PDF

129. PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway

Author

Sinha, Sutapa, primary, Price-Troska, Tammy, additional, Tian, Shulan, additional, Secreto, Charla R, additional, Wu, Xiaosheng, additional, Call, Timothy G., additional, He, Rong, additional, Parikh, Sameer A., additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Yan, Huihuang, additional, Rech, Karen L, additional, Liu, Minetta C, additional, Ansell, Stephen M., additional, Kay, Neil E., additional, and Ding, Wei, additional

Published
2018
Full Text
View/download PDF

130. Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC

Author

Scheckel, Caleb J, primary, Meyer, Megan, additional, Mi, Lanyu, additional, Slack, James L., additional, Noel, Pierre, additional, Leis, Jose F., additional, Sproat, Lisa Z., additional, Foran, James M., additional, Al-Kali, Aref, additional, Ketterling, Rhett P., additional, Hogan, William J., additional, Litzow, Mark R., additional, and Palmer, Jeanne, additional

Published
2018
Full Text
View/download PDF

131. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre

Author

Hampel, Paul J., primary, Larson, Melissa C., additional, Kabat, Brian, additional, Call, Timothy G., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Bowen, Deborah, additional, Boysen, Justin, additional, Schwager, Susan M., additional, Leis, Jose F., additional, Chanan-Khan, Asher A., additional, Muchtar, Eli, additional, Hanson, Curtis A., additional, Slager, Susan L., additional, Kay, Neil E., additional, Chaffee, Kari G., additional, Shanafelt, Tait D., additional, and Parikh, Sameer A., additional

Published
2018
Full Text
View/download PDF

132. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein–Barr virus reactivation after hematopoietic cell transplantation

Author

Jain, Tania, primary, Kosiorek, Heidi E., additional, Grys, Thomas E., additional, Kung, Shu Ting, additional, Shah, Vishal S., additional, Betcher, Jeffrey A., additional, Slack, James L., additional, Leis, Jose F., additional, Khera, Nandita, additional, Noel, Pierre, additional, Palmer, Jeanne M., additional, and Sproat, Lisa Z., additional

Published
2018
Full Text
View/download PDF

133. Abstract 1226: Rare germline variants segregating in chronic lymphocytic leukemia (CLL) families

Author

Clay-Gilmour, Alyssa I., primary, O'Brien, Daniel R., additional, Achenbach, Sara J., additional, Vachon, Celine M., additional, Chaffee, Kari G., additional, Call, Timothy G., additional, Leis, Jose F., additional, Norman, Aaron D., additional, Kabat, Brian F., additional, Parikh, Sameer A., additional, Kay, Neil E., additional, Braggio, Esteban, additional, Cerhan, James R., additional, and Slager, Susan L., additional

Published
2018
Full Text
View/download PDF

135. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis

Author

Jain, Tania, primary, Kunze, Katie L., additional, Temkit, M’hamed, additional, Partain, Daniel K., additional, Patnaik, Mrinal S., additional, Slack, James L., additional, Khera, Nandita, additional, Hogan, William J., additional, Roy, Vivek, additional, Noel, Pierre, additional, Leis, Jose F., additional, Sproat, Lisa Z., additional, Fauble, Veena, additional, Mesa, Ruben A., additional, and Palmer, Jeanne, additional

Published
2018
Full Text
View/download PDF

136. Early Fluctuations in Busulfan Levels When Using Pharmacokinetically Guided Dosing Does Not Affect Transplantation Outcomes with Busulfan-Based Conditioning Regimen

Author

Jain, Tania, primary, Kunze, Katie L., additional, Khetarpal, Banveet K., additional, McCallen, Margaret R., additional, Betcher, Jeffrey Alan, additional, Khera, Nandita, additional, Slack, James L., additional, Noel, Pierre, additional, Sproat, Lisa Z., additional, Leis, Jose F., additional, and Palmer, Jeanne, additional

Published
2018
Full Text
View/download PDF

139. Feasibility and Impact of Digital Stories Intervention on Psychosocial Well-Being among Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Study

Author

Kim, Sunny, primary, Larkey, Linda, additional, Meeker, Cody, additional, Jo, Soojung, additional, Fonseca, Rafael, additional, Leis, Jose F., additional, Mikhael, Joseph R., additional, Noel, Pierre, additional, Palmer, Jeanne, additional, Slack, James L., additional, Sproat, Lisa Z., additional, Reeder, Craig, additional, Rosenthal, Allison, additional, Langer, Shelby, additional, and Khera, Nandita, additional

Published
2018
Full Text
View/download PDF

142. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis

Author

Parikh, Sameer A., primary, Chaffee, Kari G., additional, Larson, Melissa C., additional, Hampel, Paul J., additional, Call, Timothy G., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Chanan-Khan, Asher A., additional, Conte, Michael J., additional, Bowen, Deborah, additional, Schwager, Susan M., additional, Slager, Susan L., additional, Hanson, Curtis A., additional, Kay, Neil E., additional, and Shanafelt, Tait D., additional

Published
2018
Full Text
View/download PDF

144. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

Author

Sonbol, Mohamad Bassam, primary, Hilal, Talal, additional, Dueck, Amylou C., additional, Rosenthal, Allison C., additional, Conley, Christopher R., additional, Kosiorek, Heidi E., additional, Ginos, Brenda F., additional, Gano, Katherine M., additional, Nichols, Craig S., additional, Leis, Jose F., additional, Johnston, Patrick B., additional, Habermann, Thomas M., additional, Northfelt, Donald W., additional, Bergsagel, Peter Leif, additional, Inwards, David J., additional, Witzig, Thomas E., additional, Ansell, Stephen M., additional, and Reeder, Craig B., additional

Published
2018
Full Text
View/download PDF

145. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings

Author

Hampel, Paul J., primary, Chaffee, Kari G., additional, King, Rebecca L., additional, Simonetto, Douglas, additional, Larson, Melissa C., additional, Achenbach, Sara, additional, Call, Timothy G., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Chanan-Khan, Asher A., additional, Bowen, Deborah A., additional, Conte, Michael J., additional, Schwager, Susan M., additional, Hanson, Curtis A., additional, Slager, Susan L., additional, Kay, Neil E., additional, Shanafelt, Tait D., additional, and Parikh, Sameer A., additional

Published
2017
Full Text
View/download PDF

146. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Author

Ding, Wei, primary, LaPlant, Betsy R., additional, Call, Timothy G., additional, Parikh, Sameer A., additional, Leis, Jose F., additional, He, Rong, additional, Shanafelt, Tait D., additional, Sinha, Sutapa, additional, Le-Rademacher, Jennifer, additional, Feldman, Andrew L., additional, Habermann, Thomas M., additional, Witzig, Thomas E., additional, Wiseman, Gregory A., additional, Lin, Yi, additional, Asmus, Erik, additional, Nowakowski, Grzegorz S., additional, Conte, Michael J., additional, Bowen, Deborah A., additional, Aitken, Casey N., additional, Van Dyke, Daniel L., additional, Greipp, Patricia T., additional, Liu, Xin, additional, Wu, Xiaosheng, additional, Zhang, Henan, additional, Secreto, Charla R., additional, Tian, Shulan, additional, Braggio, Esteban, additional, Wellik, Linda E., additional, Micallef, Ivana, additional, Viswanatha, David S., additional, Yan, Huihuang, additional, Chanan-Khan, Asher A., additional, Kay, Neil E., additional, Dong, Haidong, additional, and Ansell, Stephen M., additional

Published
2017
Full Text
View/download PDF

147. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

Author

Larsen, Jeremy T., primary, Shanafelt, Tait D., additional, Leis, Jose F., additional, LaPlant, Betsy, additional, Call, Tim, additional, Pettinger, Adam, additional, Hanson, Curtis, additional, Erlichman, Charles, additional, Habermann, Thomas Matthew, additional, Reeder, Craig, additional, Nikcevich, Daniel, additional, Bowen, Deborah, additional, Conte, Michael, additional, Boysen, Justin, additional, Secreto, Charla, additional, Lesnick, Connie, additional, Tschumper, Renee, additional, Jelinek, Diane, additional, Kay, Neil E., additional, and Ding, Wei, additional

Published
2017
Full Text
View/download PDF

148. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy

Author

Rosenthal, Allison, primary, Dueck, Amylou C., additional, Ansell, Stephen, additional, Gano, Katherine, additional, Conley, Christopher, additional, Nowakowski, Grzegorz S., additional, Camoriano, John, additional, Leis, Jose F., additional, Mikhael, Joseph R., additional, Keith Stewart, A., additional, Inwards, David, additional, Dingli, David, additional, Kumar, Shaji, additional, Noel, Pierre, additional, Gertz, Morie, additional, Porrata, Luis, additional, Russell, Stephen, additional, Colgan, Joseph, additional, Fonseca, Rafael, additional, Habermann, Thomas M., additional, Kapoor, Prashant, additional, Buadi, Francis, additional, Leung, Nelson, additional, Tiedemann, Rodger, additional, Witzig, Thomas E., additional, and Reeder, Craig, additional

Published
2017
Full Text
View/download PDF

150. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Author

Shanafelt, Tait D., Parikh, Sameer A., Noseworthy, Peter A., Goede, Valentin, Chaffee, Kari G., Bahlo, Jasmin, Call, Timothy G., Schwager, Susan M., Ding, Wei, Eichhorst, Barbara, Fischer, Kirsten, Leis, Jose F., Chanan-Khan, Asher Alban, Hallek, Michael, Slager, Susan L., Kay, Neil E., Shanafelt, Tait D., Parikh, Sameer A., Noseworthy, Peter A., Goede, Valentin, Chaffee, Kari G., Bahlo, Jasmin, Call, Timothy G., Schwager, Susan M., Ding, Wei, Eichhorst, Barbara, Fischer, Kirsten, Leis, Jose F., Chanan-Khan, Asher Alban, Hallek, Michael, Slager, Susan L., and Kay, Neil E.

Abstract

Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/ year). Older age (p <. 0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <. 0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results